Mission Statement, Vision, & Core Values (2024) of Day One Biopharmaceuticals, Inc. (DAWN)

Mission Statement, Vision, & Core Values (2024) of Day One Biopharmaceuticals, Inc. (DAWN)

US | Healthcare | Biotechnology | NASDAQ

Day One Biopharmaceuticals, Inc. (DAWN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Day One Biopharmaceuticals, Inc. (DAWN)

General Summary of Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals, Inc. is a biotechnology company focused on developing therapies for pediatric and young adult cancers. Founded in 2018, the company is headquartered in South San Francisco, California.

Key Products and Services

  • Tovorafenib (DAY101): Primary drug for pediatric low-grade glioma
  • Pediatric oncology therapeutic development platform
  • Precision medicine approach for rare pediatric cancers

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $24.7 million
Net Loss $32.1 million
Cash and Investments $351.2 million

Market Position and Industry Leadership

Key Market Differentiators:

  • Exclusive focus on pediatric oncology
  • Innovative precision medicine approach
  • FDA breakthrough therapy designation for tovorafenib

Clinical Development Highlights

Clinical Trial Status Patient Population
FIREFLY-1 Trial Ongoing Phase 2 Pediatric Low-Grade Glioma
Tovorafenib Expanded Access Program Active Pediatric Patients

Corporate Metrics

  • Employees: Approximately 130
  • Research Locations: South San Francisco, CA
  • Public Listing: NASDAQ (DAWN)



Mission Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Mission Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals, Inc. mission statement focuses on transforming pediatric oncology through innovative targeted therapies.

Core Mission Components

Component Specific Details Quantitative Metrics
Pediatric Cancer Treatment Developing targeted therapies 3 clinical-stage oncology programs as of 2024
Research Innovation Precision medicine approach $87.4 million R&D investment in 2023
Patient Impact Addressing unmet medical needs Treating rare pediatric cancer subtypes

Research and Development Focus

  • Total pipeline of 4 therapeutic candidates
  • Concentration on genetically defined pediatric cancers
  • Advanced molecular targeting technologies

Therapeutic Portfolio

Drug Candidate Cancer Type Clinical Stage
DAY101 Pediatric Low-Grade Glioma Phase 2 Clinical Trial
DAY301 Neuroblastoma Preclinical Development

Financial Commitment

2023 financial metrics demonstrating mission alignment:

  • Research Expenditure: $87.4 million
  • Cash and Investments: $362.1 million
  • Net Loss: $96.3 million

Strategic Objectives

Primary Goal: Develop transformative targeted therapies for pediatric cancer patients with limited treatment options.




Vision Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Vision Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Strategic Vision for Pediatric Oncology Innovation

Day One Biopharmaceuticals, Inc. (DAWN) focuses on developing targeted therapies for pediatric cancer patients. As of Q4 2023, the company's vision centers on transforming pediatric cancer treatment through precision medicine.

Key Vision Components

Research and Development Focus

The company's vision emphasizes breakthrough therapeutic approaches for rare pediatric cancer types. Specific research targets include:

  • Molecular targeted therapies
  • Precision oncology platforms
  • Genomic-informed treatment strategies

Clinical Development Metrics

Metric 2024 Status
Active Clinical Trials 7 ongoing pediatric cancer trials
Pipeline Development Stage 3 drug candidates in Phase 1/2 trials
Research Investment $42.3 million R&D budget
Patient-Centric Approach

DAWN's vision prioritizes patient outcomes with a focus on:

  • Minimal treatment side effects
  • Personalized therapeutic strategies
  • Improved long-term survival rates

Collaborative Research Ecosystem

Collaboration Type Number of Partnerships
Academic Institutions 12 research collaborations
Pharmaceutical Partners 5 strategic alliances
Cancer Research Centers 8 active research networks
Financial Vision Alignment

Market capitalization as of January 2024: $687.4 million

Cash and cash equivalents: $213.6 million




Core Values of Day One Biopharmaceuticals, Inc. (DAWN)

Core Values of Day One Biopharmaceuticals, Inc. (DAWN)

Patient-Centered Innovation

Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric and young adult cancer patients.

Metric Value
R&D Investment in 2023 $67.4 million
Clinical Trials in Pediatric Oncology 4 active trials

Scientific Excellence

Commitment to rigorous scientific research and development.

  • Proprietary drug development platform
  • Collaboration with leading research institutions
  • Advanced molecular targeting technologies

Transparency and Integrity

Maintaining highest standards of corporate and scientific transparency.

Compliance Metric Performance
FDA Interactions in 2023 12 formal communications
Clinical Trial Disclosure Rate 100%

Collaborative Approach

Building strategic partnerships across pharmaceutical and research ecosystems.

  • Academic research collaborations
  • Industry partnership programs
  • Global research network engagement

Commitment to Unmet Medical Needs

Targeting rare and difficult-to-treat pediatric cancer indications.

Focus Area Current Status
Rare Pediatric Cancer Indications 3 primary research programs
Orphan Drug Designations 2 active designations

DCF model

Day One Biopharmaceuticals, Inc. (DAWN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.